Rationally Designed Redox-Active Au(I) N-Heterocyclic Carbene: An Immunogenic Cell Death Inducer

Overview

Journal J Am Chem Soc

Publisher American Chemical Society

Specialty Chemistry

Date 2020 Nov 25

PMID 33237764

Citations 22

Authors

Sajal Sen

Stephanie Hufnagel

Esther Y Maier

Isaiah Aguilar

Jayaraman Selvakumar

Jennie E DeVore

Vincent M Lynch

Kuppuswamy Arumugam

Zhengrong Cui

Jonathan L Sessler

Jonathan F Arambula

Affiliations

Soon will be listed here.

Abstract

Immunogenic cell death (ICD) is a way of reengaging the tumor-specific immune system. ICD can be induced by treatment with chemotherapeutics. However, only a limited number of drugs and other treatment modalities have been shown to elicit the biomarker responses characteristic of ICD and to provide an anticancer benefit in vivo. Here, we report a rationally designed redox-active Au(I) bis-N-heterocyclic carbene that induces ICD both in vitro and in vivo. This work benefits from a synthetic pathway that allows for the facile preparation of asymmetric redox-active Au(I) bis-N-heterocyclic carbenes.

Citing Articles

Cyclometalated iridium(III) complex based on isoquinoline alkaloid synergistically elicits the ICD response and IDO inhibition autophagy-dependent ferroptosis.

Lu Y, Wang S, Li M, Liu R, Zhu M, Yang L Acta Pharm Sin B. 2025; 15(1):424-437.

PMID: 40041919 PMC: 11873580. DOI: 10.1016/j.apsb.2024.06.017.

Leveraging Immunogenic Cell Death to Enhance the Immune Response against Malignant Pleural Mesothelioma Tumors.

Chang M, Matnurov E, Wu C, Arakelyan J, Choe H, Kushnarev V J Am Chem Soc. 2025; 147(9):7908-7920.

PMID: 39992709 PMC: 11887451. DOI: 10.1021/jacs.4c17966.

Quinizarin Gold(I) N-Heterocyclic Carbene Complexes with Synergistic Activity Against Anthracycline-Resistant Leukaemia Cells: Synthesis and Biological Activity Studies.

Steinbrueck A, Reback M, Rumancev C, Siegmund D, Garrevoet J, Falkenberg G Chemistry. 2025; 31(11):e202404147.

PMID: 39757433 PMC: 11840658. DOI: 10.1002/chem.202404147.

Strategically engineered Au(I) complexes for orchestrated tumor eradication via chemo-phototherapy and induced immunogenic cell death.

Feng N, Peng Z, Zhang X, Lin Y, Hu L, Zheng L Nat Commun. 2024; 15(1):8187.

PMID: 39294133 PMC: 11410803. DOI: 10.1038/s41467-024-52458-4.

Sensitize Tumor Immunotherapy: Immunogenic Cell Death Inducing Nanosystems.

Peng J, Li S, Ti H Int J Nanomedicine. 2024; 19:5895-5930.

PMID: 38895146 PMC: 11184231. DOI: 10.2147/IJN.S457782.

References

Gopinath P, Mahammed A, Ohayon S, Gross Z, Brik A . Understanding and predicting the potency of ROS-based enzyme inhibitors, exemplified by naphthoquinones and ubiquitin specific protease-2. Chem Sci. 2017; 7(12):7079-7086. PMC: 5355956. DOI: 10.1039/c6sc02758j. View

Michalska M, Grudzien K, Malecki P, Grela K . Gold(I)-Catalyzed Formation of Naphthalene/Acenaphthene Heterocyclic Acetals. Org Lett. 2018; 20(4):954-957. DOI: 10.1021/acs.orglett.7b03856. View

Zitvogel L, Galluzzi L, Smyth M, Kroemer G . Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity. 2013; 39(1):74-88. DOI: 10.1016/j.immuni.2013.06.014. View

Kroemer G, Galluzzi L, Kepp O, Zitvogel L . Immunogenic cell death in cancer therapy. Annu Rev Immunol. 2012; 31:51-72. DOI: 10.1146/annurev-immunol-032712-100008. View

Tesniere A, Schlemmer F, Boige V, Kepp O, Martins I, Ghiringhelli F . Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene. 2009; 29(4):482-91. DOI: 10.1038/onc.2009.356. View

Krysko D, Garg A, Kaczmarek A, Krysko O, Agostinis P, Vandenabeele P . Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer. 2012; 12(12):860-75. DOI: 10.1038/nrc3380. View

Iams W, Porter J, Horn L . Immunotherapeutic approaches for small-cell lung cancer. Nat Rev Clin Oncol. 2020; 17(5):300-312. PMC: 7212527. DOI: 10.1038/s41571-019-0316-z. View

Sen S, Li Y, Lynch V, Arumugam K, Sessler J, Arambula J . Expanding the biological utility of bis-NHC gold(i) complexes through post synthetic carbamate conjugation. Chem Commun (Camb). 2019; 55(71):10627-10630. PMC: 7039396. DOI: 10.1039/c9cc05635a. View

Terenzi A, Pirker C, Keppler B, Berger W . Anticancer metal drugs and immunogenic cell death. J Inorg Biochem. 2016; 165:71-79. DOI: 10.1016/j.jinorgbio.2016.06.021. View

10.

Eriksson S, Prast-Nielsen S, Flaberg E, Szekely L, Arner E . High levels of thioredoxin reductase 1 modulate drug-specific cytotoxic efficacy. Free Radic Biol Med. 2009; 47(11):1661-71. DOI: 10.1016/j.freeradbiomed.2009.09.016. View

11.

Casares N, Pequignot M, Tesniere A, Ghiringhelli F, Roux S, Chaput N . Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med. 2005; 202(12):1691-701. PMC: 2212968. DOI: 10.1084/jem.20050915. View

12.

Tang L, Cai D, Qin M, Lu S, Hu M, Ruan S . Oxaliplatin-Based Platinum(IV) Prodrug Bearing Toll-like Receptor 7 Agonist for Enhanced Immunochemotherapy. ACS Omega. 2020; 5(1):726-734. PMC: 6964279. DOI: 10.1021/acsomega.9b03381. View

13.

Yamazaki T, Buque A, Ames T, Galluzzi L . PT-112 induces immunogenic cell death and synergizes with immune checkpoint blockers in mouse tumor models. Oncoimmunology. 2020; 9(1):1721810. PMC: 7028345. DOI: 10.1080/2162402X.2020.1721810. View

14.

Huang K, Wang F, Feng H, Luo H, Long Y, Zou T . An aminophosphonate ester ligand-containing platinum(ii) complex induces potent immunogenic cell death in vitro and elicits effective anti-tumour immune responses in vivo. Chem Commun (Camb). 2019; 55(87):13066-13069. DOI: 10.1039/c9cc06563f. View

15.

Davies K, Doroshow J, Hochstein P . Mitochondrial NADH dehydrogenase-catalyzed oxygen radical production by adriamycin, and the relative inactivity of 5-iminodaunorubicin. FEBS Lett. 1983; 153(1):227-30. DOI: 10.1016/0014-5793(83)80153-7. View

16.

Lee Y, Tan Y, Oon C . Molecular targeted therapy: Treating cancer with specificity. Eur J Pharmacol. 2018; 834:188-196. DOI: 10.1016/j.ejphar.2018.07.034. View

17.

Wong D, Ong W, Ang W . Induction of immunogenic cell death by chemotherapeutic platinum complexes. Angew Chem Int Ed Engl. 2015; 54(22):6483-7. DOI: 10.1002/anie.201500934. View

18.

Inoue H, Tani K . Multimodal immunogenic cancer cell death as a consequence of anticancer cytotoxic treatments. Cell Death Differ. 2013; 21(1):39-49. PMC: 3857623. DOI: 10.1038/cdd.2013.84. View

19.

Garg A, Dudek-Peric A, Romano E, Agostinis P . Immunogenic cell death. Int J Dev Biol. 2015; 59(1-3):131-40. DOI: 10.1387/ijdb.150061pa. View

20.

Yue S, Luo M, Liu H, Wei S . Recent Advances of Gold Compounds in Anticancer Immunity. Front Chem. 2020; 8:543. PMC: 7338717. DOI: 10.3389/fchem.2020.00543. View